Cencora, Inc. (LON: 0HF3)
London
· Delayed Price · Currency is GBP · Price in USD 246.32
+1.72 (0.70%)
Jan 22, 2025, 7:10 PM BST
Cencora Revenue
In the fiscal year ending September 30, 2024, Cencora had annual revenue of $293.96B USD with 12.12% growth. Cencora had revenue of $79.05B in the quarter ending September 30, 2024, with 14.69% growth.
Revenue
$293.96B
Revenue Growth
+12.12%
P/S Ratio
n/a
Revenue / Employee
$6.39M
Employees
46,000
Market Cap
38.76B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 293.96B | 31.79B | 12.12% |
| Sep 30, 2023 | 262.17B | 23.59B | 9.89% |
| Sep 30, 2022 | 238.59B | 24.60B | 11.50% |
| Sep 30, 2021 | 213.99B | 24.09B | 12.69% |
| Sep 30, 2020 | 189.89B | 10.30B | 5.74% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 38.20B |
| GSK plc | 31.31B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| ConvaTec Group | 1.74B |
| Hikma Pharmaceuticals | 2.39B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |
Cencora News
- 15 days ago - Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release - Business Wire
- 20 days ago - Cencora raises annual profit forecast - Reuters
- 20 days ago - Cencora Completes Acquisition of Retina Consultants of America - Business Wire
- 6 weeks ago - Cencora Closes $1.8 Billion Senior Notes Offering - Business Wire
- 6 weeks ago - Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers - Business Wire
- 6 weeks ago - Cencora: Competitive Advantages Defined - Seeking Alpha
- 7 weeks ago - Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035 - Business Wire
- 2 months ago - Cencora to Host Inaugural Product Showcase - Business Wire